A.I. in New Drug Discovery and Development Takes Center Stage at New York Health Forum (226330.KQ) – Yahoo Finance

New York, NY —News Direct— Syntekabio, Inc.

The 19th Nyc Health Forum, hosted by W Medical Strategy Group, celebrated its year end on Nov. 28 with a successful gathering of physicians, executives plus policymakers from biomedical, pharmatech and government organizations at the Press Lounge in Hudson Yards, Manhattan’s newest business and cultural hub.

Led by Syntekabio CEO Jongsun Jung, executives of Syntekabio USA   (226330: KQ)(226330: KS) joined the exclusive dinner event to meet and network with health industry leaders and innovators from the U. S. and Korea. They shared presentations and conversations on healthcare market trends and technologies while soaking in a breathtaking view of New York’s famed skyscrapers and city lights.

Syntekabio CEO Jong-sun Jung with the Syntekabio USA team.

Syntekabio CEO Jong-sun Jung with the Syntekabio USA team.

The New York Wellness Forum is well known for bringing together global wellness industry stakeholders to connect and illuminate timely topics that impact the development and businesses of biomedicine and life sciences. During the pandemic, the forum hosted a year-long series of webinars online.

Sanghee Kim, minister counselor at the Embassy associated with the Republic of Korea, and DoHyun Cho, Ph. D., chairman of the particular Ny Health Forum, warmly welcomed the guests. The robust information seminar soon followed on breaking into the Circumstance. S. health care market through collaborative global partnerships. Featured presentations included KHIDI’s roles in assisting Korean companies’ entry in to the U. S. healthcare industry simply by Soonmahn Park, Ph. D., president of KHIDI UNITED STATES, and the particular state associated with A. I. in new drug discovery and advancement by Kilyoung Kim, Ph level. D., president of Syntekabio USA.

According to Kim, Syntekabio’s groundbreaking AI platform DeepMatcher® efficiently performs tasks critical for discovering brand new synthetic drug candidates on a massive scale. DeepMatcher® is able to screen more than 1 billion compounds per target protein. The power of biotech innovation is captured within the way it virtually combines three-dimensional binding structures to predict and quickly derive accurately small molecule drug candidates. A biopharmaceutical game changer, Syntekabio’s latest cloud platform system will launch in the Circumstance. S. before the end of the year 2022.

During the dinner, Dr. Sanghyun Alex Kim, MD, president of KAMPANY, introduced the vision of Korean American doctors and his work as associate professor associated with Surgery in the Icahn School of Medicine at Mount Sinai. Several physicians also shared their views on how today’s rapidly evolving technologies are impacting their mission in treating patients, including leveraging A. I. -based cloud systems such as Syntekabio’s suite of cloud platforms.

Attendees furthermore learned about the particular global health care industry styles and the latest systems disrupting the particular marketplace. Peter Lee, director of InnoTherapyAmerica Inc. spoke about InnoTherapy technology’s advantages. Seung Woo Song, vice president associated with Psomagen, updated the audience on the genomics/proteomics clinical research services they provide.

Moderated by James Bae, senior advisor of New York Health Discussion board, the program highlighted opportunities and challenges for the U. S. -Korea pharma industry both in short- and long-term perspectives. The particular event continued well into the evening with guests, which includes U. S. representative Han S. Bang of ST Pharm, the Dong-A company; Dr. Isabella Park, the particular Korean medical program head for Northwell Health; plus Dr. Yoojin Kim, an internist for Montefiore, to name a few. To learn more about Syntekabio USA, visit https://www.syntekabio.com/eng .


SyntekaBio will be a global artificial intelligence (AI) and big data-based drug finding and growth company, headquartered in South Korea since 2009, with its U. H. operations bringing innovative technology and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people’s lives. Find out more regarding DeepMatcher®, NEO-ARS™, NGS-ARS™ plus PGM-ARS™ at www.syntekabio.com.

Contact Details

Sabina Lee

+1 201-408-5342

[email protected] org

Company Website


View source version on newsdirect. com: https://newsdirect.com/news/a-i-in-new-drug-discovery-and-development-takes-center-stage-at-new-york-health-forum-226330-kq-841078364